| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| 5-氮杂-2'-脱氧胞嘧啶核苷; 5-Aza-2'-deoxycytidine | CFN90007 | 2353-33-5 | C8H12N4O4 = 228.21 | 20mg | QQ客服：215959384 |
| 酒石酸伐仑克林; Varenicline tartrate | CFN90008 | 375815-87-5 | C13H13N3.C4H6O6 = 361.35 | 5mg | QQ客服：2056216494 |
| 盐酸帕洛诺司琼; Palonosetron hydrochloride | CFN90009 | 135729-62-3 | C19H25ClN2O = 332.87 | 20mg | QQ客服：3257982914 |
| 卡奈替尼； 卡耐替尼; Canertinib | CFN90010 | 267243-28-7 | C24H25ClFN5O3 = 485.94 | 20mg | QQ客服：3257982914 |
| 吉非替尼; Gefitinib | CFN90011 | 184475-35-2 | C22H24ClFN4O3 = 446.9 | 20mg | QQ客服：2056216494 |
| 霹雳萝芙木碱; Perakine | CFN98673 | 4382-56-3 | C21H22N2O3 = 350.4 | 5mg | QQ客服：2159513211 |
| 哈尔碱； 哈尔明碱； 肉叶云香碱； 去氢骆驼蓬碱; Harmine | CFN98676 | 442-51-3 | C13H12N2O = 212.3 | 20mg | QQ客服：3257982914 |
| 它波宁/ 水甘草碱; Tabersonine | CFN98678 | 4429-63-4 | C21H24N2O2 = 336.4 | 20mg | QQ客服：1413575084 |
| 索拉非尼; Sorafenib | CFN90012 | 284461-73-0 | C21H16ClF3N4O3 = 464.83 | 20mg | QQ客服：3257982914 |
| 普瑞巴林; Pregabalin | CFN90013 | 148553-50-8 | C8H17NO2 = 159.23 | 5mg | QQ客服：1457312923 |
| 决奈达隆; Dronedarone | CFN90014 | 141626-36-0 | C31H44N2O5S = 556.76 | 20mg | QQ客服：2159513211 |
| 达沙替尼水合物; Dasatinib monohydrate | CFN90015 | 863127-77-9 | C22H28ClN7O3S = 506.02 | 5mg | QQ客服：215959384 |
| 10-羟基二氢派利文碱; 10-Hydroxydihydroperaksine | CFN98684 | 451478-47-0 | C19H24N2O3 = 328.4 | 5mg | QQ客服：2159513211 |
| 盐酸普拉克索; Pramipexole dihydrochloride | CFN90019 | 104632-25-9 | C10H19Cl2N3S = 284.25 | 5mg | QQ客服：2159513211 |
| 雷美替胺; Ramelteon | CFN90021 | 166597-26-9 | C13H21NO2 = 259.34 | 5mg | QQ客服：2056216494 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)